X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (905) 905
Patent (885) 885
Conference Proceeding (19) 19
Publication (17) 17
Newspaper Article (5) 5
Book Chapter (3) 3
Book Review (2) 2
Dissertation (2) 2
Paper (2) 2
Report (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
electricity (392) 392
physics (272) 272
electric communication technique (244) 244
humans (220) 220
index medicus (185) 185
male (184) 184
performing operations (178) 178
transporting (178) 178
female (171) 171
basic electric elements (144) 144
aged (139) 139
middle aged (136) 136
mechanical engineering (130) 130
blasting (129) 129
heating (129) 129
lighting (129) 129
weapons (129) 129
oncology (119) 119
general tagging of cross-sectional technologies spanning over several sections of the ipc (113) 113
general tagging of new technological developments (113) 113
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (113) 113
adult (110) 110
optics (108) 108
selecting (107) 107
transmission (86) 86
optical elements, systems, or apparatus (85) 85
pictorial communication, e.g. television (85) 85
chemistry (81) 81
fixed constructions (81) 81
technical subjects covered by former uspc (75) 75
metallurgy (74) 74
human necessities (72) 72
chemotherapy (69) 69
lung neoplasms - drug therapy (66) 66
accessories therefor (63) 63
analysis (62) 62
cancer (61) 61
carcinoma, non-small-cell lung - drug therapy (57) 57
treatment outcome (56) 56
engineering elements and units (54) 54
general measures for producing and maintaining effectivefunctioning of machines or installations (54) 54
thermal insulation in general (54) 54
transmission of digital information, e.g. telegraphiccommunication (54) 54
lung cancer (52) 52
hygiene (50) 50
medical or veterinary science (50) 50
multiplex communication (50) 50
conversion or distribution of electric power (49) 49
generation (49) 49
lung neoplasms - pathology (49) 49
technical subjects covered by former us classification (48) 48
aged, 80 and over (46) 46
current collectors (46) 46
electric solid state devices not otherwise provided for (46) 46
line connectors (46) 46
semiconductor devices (46) 46
handcuffs (45) 45
keys (45) 45
locks (45) 45
safes (45) 45
window or door fittings (45) 45
animals (44) 44
education (44) 44
advertising (43) 43
cryptography (43) 43
display (43) 43
lung cancer, non-small cell (43) 43
prognosis (43) 43
seals (43) 43
arrangements or circuits for control of indicating devicesusing static means to present variable information (42) 42
research (42) 42
antineoplastic combined chemotherapy protocols - therapeutic use (41) 41
technologies or applications for mitigation or adaptation againstclimate change (41) 41
cinematography (40) 40
electrography (40) 40
holography (40) 40
photography (40) 40
vehicles in general (40) 40
calculating (39) 39
computing (39) 39
counting (39) 39
devices or arrangements, the optical operation of which ismodified by changing the optical properties of the medium of thedevices or arrangements for the control of the intensity,colour, phase, polarisation or direction of light, e.g.switching, gating, modulating or demodulating (38) 38
frequency-changing (38) 38
japan (38) 38
neoplasm staging (38) 38
non-linear optics (38) 38
optical analogue/digital converters (38) 38
optical logic elements (38) 38
techniques or procedures for the operation thereof (38) 38
artificial respiration (37) 37
bathing devices for special therapeutic or hygienic purposesor specific parts of the body (37) 37
massage (37) 37
medicine & public health (37) 37
physical therapy apparatus, e.g. devices for locating orstimulating reflex points in the body (37) 37
mutation (35) 35
care and treatment (34) 34
measuring (33) 33
testing (33) 33
medical research (32) 32
tumors (32) 32
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1715) 1715
French (190) 190
German (157) 157
Japanese (127) 127
Chinese (47) 47
Korean (10) 10
Portuguese (5) 5
Spanish (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | ADENOCARCINOMA | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell
Journal Article
Cancer Science, ISSN 1347-9032, 05/2017, Volume 108, Issue 5, pp. 1000 - 1006
Journal Article
International Journal of Hematology, ISSN 0925-5710, 12/2012, Volume 96, Issue 6, pp. 748 - 757
Invasive fungal infection (IFI) causes morbidity and mortality among patients with hematological malignancies who receive cytotoxic chemotherapy or... 
Candidiasis | Antifungal agent | Medicine & Public Health | Hematology | Aspergillosis | Oncology | Invasive fungal infection | Hematological malignancy | ACUTE MYELOID-LEUKEMIA | LOW-SENSITIVITY | RECIPIENTS | DISEASES SOCIETY | LIPOSOMAL AMPHOTERICIN-B | CLINICAL-PRACTICE GUIDELINES | CARE CANCER CENTER | ANTIFUNGAL THERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Japan - epidemiology | Mycoses - epidemiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Mycoses - microbiology | Infant | Male | Antifungal Agents - therapeutic use | Neutropenia - complications | Opportunistic Infections - etiology | Stem Cell Transplantation | Young Adult | Adult | Female | Retrospective Studies | Hematologic Neoplasms - complications | Postoperative Complications - drug therapy | Neutropenia - chemically induced | Catheter-Related Infections - epidemiology | Child | Invasive Pulmonary Aspergillosis - epidemiology | Invasive Pulmonary Aspergillosis - drug therapy | Opportunistic Infections - epidemiology | Treatment Outcome | Combined Modality Therapy | Postoperative Complications - epidemiology | Catheter-Related Infections - drug therapy | Hematologic Neoplasms - surgery | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Opportunistic Infections - drug therapy | Adolescent | Mycoses - drug therapy | Hematologic Neoplasms - drug therapy | Aged | Immunocompromised Host | Mycoses - etiology | Medical colleges | Care and treatment | Patient outcomes | Mortality | Leukemia | Antifungal agents | Mycoses | Transplantation | Epidemiology | Hematopoietic stem cells | Chemotherapy | Analysis | Lymphomas | Children | Health aspects | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Medical services | Metastasis | Kinases | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals
Journal Article
by Garassino, Marina Chiara and Cho, Byoung-Chul and Kim, Dong-Wan and Kim, Joo-Hang and Kim, Sang-We and Kim, Young-Chul and Mazières, Julien and Vansteenkiste, Johan and Lena, Hervé and Corral Jaime, Jesus and Gray, Jhanelle E and Powderly, John and Chouaid, Christos and Bidoli, Paolo and Wheatley-Price, Paul and Park, Keunchil and Soo, Ross A and Huang, Yifan and Wadsworth, Catherine and Dennis, Phillip A and Rizvi, Naiyer A and Paz-Ares Rodriguez, Luis and Novello, Silvia and Hiret, Sandrine and Schmid, Peter and Laack, Eckart and Califano, Raffaele and Maemondo, Makoto and Chaft, Jamie and Vicente Baz, David and Berghmans, Thierry and Surmont, Veerle and Reck, Martin and Han, Ji-Youn and Holgado Martin, Esther and Belda Iniesta, Cristobal and Oe, Yuichiro and Chella, Antonio and Chopra, Akhil and Robinet, Gilles and Soto Parra, Hector and Thomas, Michael and Cheema, Parneet and Katakami, Nobuyuki and Su, Wu-Chou and Wolf, Juergen and Lee, Jong-Seok and Saka, Hideo and Milella, Michele and Ramos Garcia, Inmaculada and Sibille, Anne and Yokoi, Takashi and Kang, Eun Joo and Atagi, Shinji and Spaeth-Schwalbe, Ernst and Nishio, Makoto and Imamura, Fumio and Gabrail, Nashat and Veillon, Remi and Derijcke, Sofie and Maeda, Tadashi and Zylla, Dylan and Kubiak, Kendra and Santoro, Armando and Uy, Ma. Noemi and Lucien Geater, Sarayut and Italiano, Antoine and Kowalski, Dariusz and Barlesi, Fabrice and Chen, Yuh-Min and Spigel, David and Chewaskulyong, Busyamas and Garcia Gomez, Ramon and Alvarez Alvarez, Rosa and Yang, Chih-Hsin and Hsia, Te-Chun and Denis, Fabrice and Sakai, Hiroshi and Vincent, Mark and Goto, Koichi and Bosch-Barrera, Joaquim and Weiss, Glen and Canon, Jean-Luc and Scholz, Christian and Aglietta, Massimo and Kemmotsu, Hirotsugu and Azuma, Koichi and Bradbury, Penelope and Feld, Ronald and Chachoua, Abraham and Jassem, Jacek and Juergens, Rosalyn and Palmero Sanchez, Ramon and Malcolm, Albert and Vrindavanam, Nandagopal and Kubota, Kaoru and Waller, Cornelius and Waterhouse, David and Coudert, Bruno and Mark, Zsuzsanna and ... and ATLANTIC Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 521 - 536
Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without tyrosine kinase or anaplastic... 
MULTICENTER | METAANALYSIS | NSCLC | ONCOLOGY | RANDOMIZED CONTROLLED-TRIAL | ATEZOLIZUMAB | IMMUNE CHECKPOINT | NIVOLUMAB | MEDI4736 | CLINICAL ACTIVITY | DOCETAXEL | Lung cancer, Non-small cell | Care and treatment
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 874 - 886
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 663 - 671
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 2/2017, Volume 22, Issue 1, pp. 70 - 78
In Japan, the clinical efficacy of erlotinib monotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer was... 
EGFR mutations | Medicine & Public Health | Erlotinib | Non-small-cell lung cancer (NSCLC) | First line | Oncology | Cancer Research | Japanese patients | Overall survival | Surgical Oncology | GEFITINIB | NSCLC | CHEMOTHERAPY | TYROSINE KINASE INHIBITORS | IMPACT | THERAPY | CISPLATIN | ONCOLOGY | BRAIN METASTASES | AFATINIB | PROGRESSION | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Aged, 80 and over | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Erlotinib Hydrochloride - administration & dosage | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Research Design | Epidermal growth factor | Gene mutations | Analysis | Oncology, Experimental | Patient outcomes | Research | Lung cancer, Non-small cell | Cancer | Original
Journal Article